BIO-TECHNE Corp Intangible Assets, Net (Excluding Goodwill)
BIO-TECHNE Corp (TECH) had Intangible Assets, Net (Excluding Goodwill) of $303.46 million as of 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2026-08-24
- 2026-06-30: Intangible Assets, Net (Excluding Goodwill) $303.46M.
- 2026-03-31: Intangible Assets, Net (Excluding Goodwill) $319.07M.
- 2025-12-31: Intangible Assets, Net (Excluding Goodwill) $334.99M.
- 2025-09-30: Intangible Assets, Net (Excluding Goodwill) $350.11M.
| Period end | Intangible Assets, Net (Excluding Goodwill) | Intangible Assets, Net (Excluding Goodwill) as first filed |
|---|---|---|
| 2026-06-30 | $303.46M 10-K · filed 2026-08-24 | |
| 2026-03-31 | $319.07M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $334.99M 10-Q · filed 2026-02-04 | |
| 2025-09-30 | $350.11M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $365.60M 10-K · filed 2026-08-24 | |
| 2025-03-31 | $443.70M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $461.05M 10-Q · filed 2025-02-06 | |
| 2024-09-30 | $486.00M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $507.08M 10-K · filed 2026-08-24 | |
| 2024-03-31 | $526.43M 10-Q · filed 2024-05-06 | |
| 2023-12-31 | $550.61M 10-Q · filed 2024-02-07 | |
| 2023-09-30 | $578.97M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $534.64M 10-K · filed 2025-08-22 | |
| 2023-03-31 | $553.26M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $567.65M 10-Q · filed 2023-02-07 | |
| 2022-09-30 | $585.53M 10-Q · filed 2022-11-07 | |
| 2022-06-30 | $531.52M 10-K · filed 2024-08-22 | |
| 2022-03-31 | $551.34M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $569.35M 10-Q · filed 2022-02-07 | |
| 2021-09-30 | $615.97M 10-Q · filed 2022-02-07 | $596.30M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $615.97M 10-K · filed 2023-08-23 | |
| 2021-03-31 | $489.18M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $504.17M 10-Q · filed 2021-02-08 | |
| 2020-09-30 | $507.59M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $516.54M 10-K · filed 2022-08-24 | |
| 2020-03-31 | $530.33M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $549.71M 10-Q · filed 2020-02-06 | |
| 2019-09-30 | $563.34M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $579.43M 10-K · filed 2021-08-25 | |
| 2019-03-31 | $579.14M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $608.27M 10-Q · filed 2019-02-07 | |
| 2018-09-30 | $632.69M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $446.33M 10-K · filed 2020-08-26 | |
| 2018-03-31 | $443.79M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $438.36M 10-Q · filed 2018-02-08 | |
| 2017-09-30 | $451.02M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $452.04M 10-K/A · filed 2019-11-06 | |
| 2017-03-31 | $482.69M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $493.54M 10-Q · filed 2017-02-09 | |
| 2016-09-30 | $503.63M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $310.52M 10-K · filed 2018-08-27 | |
| 2015-06-30 | $292.84M 10-K · filed 2017-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |